Direkt zum Inhalt
Merck
Alle Fotos(1)

Dokumente

HFIB1-100K

Millipore

MILLIPLEX® Human Fibrosis Panel 1

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

UNSPSC-Code:
12161503
NACRES:
NA.47

Speziesreaktivität

human

Hersteller/Markenname

Milliplex®

assay range

accuracy: 95-96%
standard curve range: 10-40,000 pg/mL
(for COMP)

standard curve range: 2-10,000 pg/mL
(for IL-18BPa)

standard curve range: 6-25,000 pg/mL
(for Uteroglobin)

inter-assay cv: <20%
intra-assay cv: <10%

Methode(n)

multiplexing: suitable

Nachweisverfahren

fluorometric (Luminex® xMAP®)

Versandbedingung

wet ice

Lagertemp.

2-8°C

Allgemeine Beschreibung

Fibrosis is a pathological wound healing response that is common to many chronic diseases and injuries. The abnormal wound healing response of fibrosis involves the excessive accumulation of the extracellular matrix components responsible for the formation of scar tissue. Progressive tissue scarring causes alterations to normal organ structure leading to dysfunction and failure. Fibrosis and related diseases are responsible for an increasing burden of morbidity and mortality worldwide. This panel of fibrosis-related biomarkers enables researchers to advance understanding of the complex processes associated with fibrotic diseases, including but not limited to idiopathic pulmonary fibrosis, liver fibrosis, and lung fibrosis.

Our MILLIPLEX® Human Fibrosis Panel 1 is a 3-plex kit to be used for the simultaneous quantification of any or all of the following analytes in serum, plasma and tissue culture samples:
IL-18 Binding Protein A (IL-18BPa), Cartilage Oligomeric Matrix Protein (COMP), and Uteroglobin.

MILLIPLEX® offers the broadest selection of analytes across a wide range of disease states and species. Once the analytes of interest have been identified, you can rely on the quality that we build into each kit to produce results you can trust. In addition to the assay characteristics listed in the protocol, other performance criteria evaluated during the verification process include: cross-reactivity, dilution linearity, kit stability, and sample behavior (e.g. detectability and stability).

Each MILLIPLEX® panel and kit includes:
  • Quality controls (QCs) to qualify assay performance
  • Comparison of standard (calibrator) and QC lots to a reference lot to ensure lot-to-lot consistency
  • Optimized serum matrix to mimic native analyte environment in serum and plasma samples
  • Detection antibody cocktails designed to yield consistent analyte profiles within panel

In addition each panel and kit meets stringent manufacturing criteria to ensure batch-to-batch reproducibility. The MILLIPLEX® Human Fibrosis Panel 1 thus enables you to focus on the therapeutic potential of cytokines and the modulation of cytokine expression. Coupled with the Luminex® xMAP® platform in a magnetic bead format, you receive the advantage of ideal speed and sensitivity, allowing quantitative multiplex detection of dozens of analytes simultaneously, which can dramatically improve productivity.

Spezifität

Cross Reactivity:
Negligible or no cross-reactivity was observed between the antibodies for any one analyte and any of the other analytes in this panel.

Anwendung

The Human Fibrosis Panel 1, using the Luminex® xMAP® technology, enables simultaneous quantification of 3 fibrosis protein biomarkers in human serum, plasma and tissue/cell culture samples.

  • This assay may be run overnight (16-18 hours) at 2-8°C or for 2 hours at room temperature (20-25°C) with agitation on a plate shaker.
  • A maximum of 25 μL per well of 1:200 serum or plasma diluted in Assay Buffer should be used for all analytes. Tissue culture supernatants may require dilution in appropriate control medium.
  • Tissue/cell extracts should be prepared in neutral buffers containing reagents and conditions that do not interfere with assay performance.
Assay Requirements:
Researchers will need access to a Luminex® 200, MAGPIX, or FLEXMAP 3D instrument.

Analytes Available:
  • COMP
  • IL-18BPa
  • Uteroglobin

Research Category:
  • Inflammation & Immunology

Research Sub-Category:
  • Inflammation & Autoimmune Mechanisms
  • Inflammation
  • Infectious Diseases
  • Cytokines & Cytokine Receptors
  • Growth Factors & Receptors
  • Oncology
  • Obesity
  • Metabolic Disorders
  • Autoimmune disease
  • Cardiovascular Disease

Leistungsmerkmale und Vorteile

Configuration:
Design your multiplex kit by choosing available analytes within this panel.

Verpackung

96 well plate

Rechtliche Hinweise

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Haftungsausschluss

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Signalwort

Danger

Gefahreneinstufungen

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

Zielorgane

Respiratory Tract

WGK

WGK 3


Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.